Advertisement

Topics

Chiesi Group Company Profile

07:06 EST 18th November 2017 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [287 Associated News Articles listed on BioPortfolio]

Triple-combo superior in COPD, Chiesi says

Chiesi Farmaceutici claims that the Phase IIIb TRIBUTE study has shown for the first time the superiority…

NICE recommends Chiesi's limbal stem cell deficiency drug

A final guidance document was issued by the National Institute for Health and Care Excellence recommending Chiesi's Holoclar  -More- 

Protalix gives Chiesi ex-US rights to Fabry's disease treatment

Chiesi Farmaceutici gained ex-US rights to Protalix BioTherapeutics' PRX-102, or pegunigalsidase alfa, which is in late-stage -More- 

EU nod for Chiesi’s COPD therapy

European regulators have green-lighted Chiesi’s new chronic obstructive pulmonary disease (COPD) maintenance therapy Trimbow.

Chiesi Ends Collaboration with uniQure on Hemophilia B Gene Therapy Candidate

Chiesi Group has ended its four-year-old collaboration with uniQure to co-develop and license a gene therapy for hemophilia B and has returned its development and commercialization rights to the gene ...

Chiesi Group's Trimbow wins European licence

European Commission approves the COPD treatment

Chiesi gets ex-US rights to Protalix's Phase III Fabry candidate

Protalix BioTherapeutics Inc. licensed Chiesi Farmaceutici SPA exclusive rights to develop and commercialize its Phase III PRX102 (pegunigalsidase alfa) for Fabry disease in all territories except the...

Chiesi USA Breaks Ground on New Headquarters Building in Cary

CARY, NC--(Marketwired - November 02, 2017) - Chiesi USA, a specialty pharmaceutical company focused on the hospital, rare disease, and hospital-adjacent settings, broke ground today on a new corporat...

PubMed Articles [1788 Associated PubMed Articles listed on BioPortfolio]

Transcanalicular laser-assisted dacryocystorhinostomy with diode laser.

This article compares the efficacy of transcanalicular laser assisted dacryocystorhinostomy (TL DCR) with conventional external dacryocystorhinostomy (Ex DCR). All patients were randomly divided into ...

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Protective effects of Tempol in an experimental ovarian ischemia-reperfusion injury model in female Wistar Albino rats.

The aim of this study was to investigate the antioxidant effects of tempol on ovarian ischemia-reperfusion injury in rats. Forty female Wistar albino rats were randomly divided into five groups: Group...

Effects of leptin on femoral fracture in rats.

In this study, our objective was to evaluate effects of leptin on fracture healing in rats. Seventy two male Sprague-Dawley (SD) rats were randomized into 3 groups. Standardized femoral fractures were...

Keeping up appearances: Strategic information exchange by disidentified group members.

Information exchange is a crucial process in groups, but to date, no one has systematically examined how a group member's relationship with a group can undermine this process. The current research exa...

Clinical Trials [3248 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure

Random grouping by computer, divided into two groups, a group of rhubarb treatment group, another group for the placebo group.

Companies [1578 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Bioethics
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...


Corporate Database Quicklinks



Searches Linking to this Company Record